Australia's most trusted source of pharma news
Friday, 20 October 2017
Latest News
MSD's cyber losses in hundreds of millions
Cyber Terrorism: Insurers could be up for USD275 million to pay out on losses suffered by MSD (Merck) in the devastating NotPetya virus attack.
NPS MedicineWise goes into film biz
Marketing: NPS MedicineWise is looking for budding film-makers who can excite the public about bacterial resistance to antibiotics.
Fifth of top tax audits target pharma
Taxation: A 1300-strong tax avoidance taskforce is probing many pharmacos in its review of the top 1000 taxpayers.
TGA rolls dice for 2018 flu vax
Vaccines: The TGA has named the influenza strains to be included in the 2018 flu vaccines, with hopes next year's match will do a better job of protecting Australians after our deadliest season on record.
Hunt backs more OTC switches
Scheduling: Australia needs continued reform in the self-medication sector to extend greater access to non-prescription medicines, Health Minister Greg Hunt has said.
DOACs may be no safer than warfarin
Medicines Safety: Direct oral anticoagulants have a similar risk of bleeding to warfarin, a large-scale post-market study has revealed.
Earlier
Wood quits as GBMA boss
Leadership: The Generic and Biosimilar Medicines Association has
announced the resignation of CEO Belinda Wood.
Dead drug costs Gilead hundreds of millions
Companies: A report to Australia's ASIC reveals just how immensely
costly a drug development failure can be, especially when the development
company was bought at a premium price.
Janssen scraps two Aust hopefuls
Pipeline: J&J has binned two late-stage drugs - one thought to already
be before the TGA - while posting strong Q3 results on the back of pharma
division, Janssen.
MSD report calls for radical change to cancer decision-making
Reimbursement: A report commissioned by MSD and released today
calls for radical change to Australia's reimbursement system for new cancer
medicines.
Aust unlikely to see some drugs: CSL
Medicines Access: Loretta Croker, CSL's head of commercial operations,
says some of her company's drugs may never reach Australia because of the
government's attitude to funding.
Earlier
Disease awareness ads threatened
Marketing: A proposal by the TGA to revamp rules for S3 ads has
potential to confuse disease awareness campaigns says MA.
Chem Warehouse in bed with Google
Retail: Households in rural Australia will have medicines dropped into
their backyards by drones as part of a test program partnering Chemist
Warehouse with Google's parent company Alphabet.
Political mud flies in codeine war
Scheduling: Health consumer and doctor groups have waded into the
Pharmacy Guild's ongoing battle to prevent the up-scheduling of codeine while
doctors have suggested the Guild is trying to buy policy decisions.
MA agreement comes to parliament
Policy: The bill that backs the MA pact with government has been
introduced to the parliament by Health Minister Greg Hunt.
Innovate or get out says CSL's Perreault
Companies: Companies that fail to focus on innovation have no place in
today's pharma business, CSL's managing director, Paul Perreault, has told the
company's AGM.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.
Perspective
Pharma risks made crystal clear
Once in a while the size of the financial risks inherent in the drug business is made clear and the price of failure emerges as very significant.
Once in a while the size of the financial risks inherent in the drug business is made clear and the price of failure emerges as very significant.
Approvals Action
Generics target HIV combo
Generic company Lupin has registered additional competitors for ViiV's HIV combination therapy Kivexa signalling increasing interest in its forhcoming patent expiry.
Generic company Lupin has registered additional competitors for ViiV's HIV combination therapy Kivexa signalling increasing interest in its forhcoming patent expiry.